title: Functional platelet modifications induced by oral magnesium supplementation in normotensive and hypertensive pregnancy.
abstract: Platelet functionality alterations have been correlated to the onset of hypertension in pregnancy and oral Mg++ supplementation has been clinically postulated to counteract such alterations. We, therefore tested the effect of 4 weeks oral Mg++ pyrrolidone carboxylate supplementation on platelet function. Forty-eight pregnant women were enrolled in the study at the beginning of the third trimester (30-32 weeks). Twenty women were preeclamptic, while 28 remained normotensive and served as controls. All the women received 360 mg/day magnesium pyrrolidone carboxylate for 4 weeks. DPH fluorescence, Na+/K(+)-ATPase and Ca(++)-ATPase activity, intracellular free Ca++ concentrations were determined prior and after the 4-weeks supplementation. Oral Mg++ supplementation significantly increased platelet DPH fluorescence in both normotensive and preeclamptic women. In normotensive pregnant women, it also significantly increased the activity of Na+/K(+)-ATPase, the activity of Ca(++)-ATPase and reduced the concentration of intraplatelet free Ca++. In hypertensive pregnant women, Mg supplementation increases Na+/K(+)-ATPase activity and decreases intracellular free Ca++; this, in turn, contributes to reducing the activity of Ca(++)-ATPase. Magnesium supplementation to preventing hypertension in pregnancy seems to have a consistent biochemical and clinical background.
authors.affiliation: Institute of Gynecology and Obstetrics, University of Ancona.
authors.forename: A L
authors.initials: AL
authors.lastname: Tranquilli
authors.forename: L
authors.initials: L
authors.lastname: Mazzanti
authors.forename: R
authors.initials: R
authors.lastname: Staffolani
authors.forename: E
authors.initials: E
authors.lastname: Salvolini
authors.forename: G G
authors.initials: GG
authors.lastname: Garzetti
authors.forename: C
authors.initials: C
authors.lastname: Romanini
mesh_terms: D000284:Administration, Oral; D001792:Blood Platelets / Q000187:drug effects* / Q000201:enzymology; D000252:Calcium-Transporting ATPases / Q000097:blood; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood*; D008274:Magnesium / Q000494:pharmacology*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000097:blood*; D000254:Sodium-Potassium-Exchanging ATPase / Q000097:blood
chemical_list: D000252:Calcium-Transporting ATPases; D000254:Sodium-Potassium-Exchanging ATPase; D008274:Magnesium